Biomarkers in Cancer
Overview
Biomarkers in Cancer is a scientific journal, published by Sage Publications since 2009 in English. The journal's country of origin is United States.
Details
Details
Abbr.
Biomark Cancer
Publisher
Sage Publications
Start
2009
End
2019
Frequency
Annual
e-ISSN
1179-299X
Country
United States
Language
English
Recent Articles
1.
Chen Z, Yu T, Cabay R, Jin Y, Mahjabeen I, Luan X, et al.
Biomark Cancer
. 2022 Mar;
9:1179299X1700900001.
PMID: 35237086
Oral tongue squamous cell carcinoma (TSCC) is a complex disease with extensive genetic and epigenetic defects, including microRNA deregulation. The aims of the present study were to test the feasibility...
2.
Henderson M, Silver M, Borman S, Tran Q, Letsios E, Mulpuri R, et al.
Biomark Cancer
. 2022 Mar;
10:1179299X18756646.
PMID: 35237085
Ovarian cancer is often fatal and incidence in the general population is low, underscoring the necessity (and the challenges) for advancements in screening and early detection. The goal of this...
3.
Lipunova N, Wesselius A, Cheng K, van Schooten F, Cazier J, Bryan R, et al.
Biomark Cancer
. 2020 Jan;
11:1179299X19897255.
PMID: 31908559
Introduction: Many germline associations have been reported for urinary bladder cancer (UBC) outcomes and prognostic characteristics. It is unclear whether there are overlapping genetic patterns for various prognostic endpoints. We...
4.
Kusumoto H, Tashiro K, Shimaoka S, Tsukasa K, Baba Y, Furukawa S, et al.
Biomark Cancer
. 2020 Jan;
11:1179299X19896551.
PMID: 31903024
The technique used for cancer monitoring is essential for effective cancer therapy. Currently, several methods such as diagnostic imaging and biochemical markers have been used for cancer monitoring, but these...
5.
Elhassan A, Suleiman A, El Dawi N, Mohamed S
Biomark Cancer
. 2019 Sep;
11:1179299X19861957.
PMID: 31555051
Aim: Verrucous carcinoma (VC) is a low-grade rare variant of squamous cell carcinoma (SCC). Syndecan-1 (CD138) is a heparan sulfate proteoglycan which participates in cell-to-cell adhesion and cell-matrix interaction. Being...
6.
Pokhriyal R, Hariprasad R, Kumar L, Hariprasad G
Biomark Cancer
. 2019 Jul;
11:1179299X19860815.
PMID: 31308780
Ovarian cancer is the seventh most common gynaecologic malignancy seen in women. Majority of the patients with ovarian cancer are diagnosed at the advanced stage making prognosis poor. The standard...
7.
Dunton C, Bullock R, Fritsche H
Biomark Cancer
. 2019 Jun;
11:1179299X19853785.
PMID: 31236012
Objective: To review and analyze the serum values of risk of ovarian malignancy algorithm (ROMA) and multivariate index assay (MIA) in subgroups of women who underwent surgery for adnexal masses...
8.
Keskin H, Cadirci K, Demirkazik A, Akbulut H, Yalcin B
Biomark Cancer
. 2019 Jun;
11:1179299X19854447.
PMID: 31217693
Several problems such as myalgia, arthralgia, fever, dyspnea, generalized edema, and pleural effusion can occur in cancer patients following the chemotherapy, especially at the first cycle of the first chemotherapy...
9.
Woolf D, Li S, Detre S, Liu A, Gogbashian A, Simcock I, et al.
Biomark Cancer
. 2019 Jun;
11:1179299X19851513.
PMID: 31210736
Background: Tumour heterogeneity is considered an important mechanism of treatment failure. Imaging-based assessment of tumour heterogeneity is showing promise but the relationship between these mathematically derived measures and accepted 'gold...
10.
Pitari G, Cotzia P, Ali M, Birbe R, Rizzo W, Bombonati A, et al.
Biomark Cancer
. 2019 Mar;
10:1179299X18774551.
PMID: 30911223
Background And Aims: The benefit of adjuvant chemotherapy for stage II colorectal cancer (CRC) patients remains unclear, emphasizing the need for improved prognostic biomarkers to identify patients at risk of...